Parvovirus – a potentially deadly disease in puppies – has been called the world’s most common canine infectious disease. The viral infection is one that has long been battled through a preemptive vaccine regimen and treated by managing the clinical signs of the infection. However, a new innovation from Indiana-based animal health giant Elanco is transforming canine care through science. This week, we are joined by Elanco veterinarian and veterinarian technical marketer, Dr. Jennifer Miller, to talk about the newly approved monoclonal anitibody treatment for canine parvovirus.
What is parvovirus, how is it caused and what were the treatment options before Elanco’s breakthrough monoclonal antibody? Dr. Miller talks about its severity, its commonality and why this innovation was so critical for puppy owners. She also gets into the years it takes to bring innovation to market and the rewarding feeling of watching it save lives in clinics across the country.
How does this become the next wave of innovation at Elanco? Dr. Miller talks about the transferable opportunities to other animals and to human health. She also gets into the collaborative spirit working to advance the innovation ecosystem and what she sees as the future of animal health.